China Pharma Holdings, Inc. (NYSE MKT: CPHI) (“China Pharma,” the “Company” or “We”), an NYSE American listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, announced today the launch of its health product Noni Enzyme ARARATO® to the market.
Noni, also known by its scientific name as Morinda citrifolia, is a fruit-bearing tree in the coffee family, Rubiaceae. Its native range extends across tropical islands of the South Pacific, and Hainan Island, China. The strong-smelling fruit has been used in traditional medicine, and in the consumer market, it has been introduced as a supplement in various forms, such as health products, skin products, and juices.
“Noni Enzyme is rich in Proxeronine and Proxeronase, which is a natural, healthy and nutrition-rich food supplement. Noni was approved by the Chinese Ministry of Health as a new resource food in 2010,” said Ms. Zhilin Li, China Pharma’s Chairman and CEO. Ms. Li continued, “Our product ARARATO® uses high quality noni fruit grown locally in Hainan Island as its raw material, and enjoys the quality assurance system environment back-up by our facility as a pharmaceutical manufacturer. We are committed to providing a high quality Noni enzyme product to the market.”
The launch of ARARATO® represents a strategic development for our company to expand into the health product market. We believe that with the aging of the Chinese population, the growth of the middle class population, and the strengthening of national health awareness, we are in a good position to explore health products – along with our core business of pharmaceutical products – to leverage use of our facilities and sales channels to meet market needs.